Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Chemomab Ltd.

Home Clinical Trial Sponsors and OrganizationsChemomab Ltd.

Chemomab Ltd.

ACTIVE

Israelwww.chemomab.comSubsidiary

Part of Anchiano Therapeutics Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

7

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

57.1%

Phase 2

3

42.9%

Trial Status Distribution

Active, not recruiting

1

14.3%

Completed

5

71.4%

Suspended

1

14.3%

Clinical Trials

Trials sponsored by this organization (7)

Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

Sep 202645 participants

CM-101 in NASH Patients - The SPLASH Study

Feb 202123 participants

CM-101 in PSC Patients -The SPRING Study

Oct 202077 participants

Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

Mar 20198 participants

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects

Dec 201816 participants

A phase 2 study being run in multiple centres to evaluate the safety, tolerability and efficacy of a study drug (called CM-101) which will be given to patients with primary sclerosing cholangitis for 12 weeks.

Active, not recruiting

Nov 201830 participants

Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

Jul 201732 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials7
Approvals
News

Back to Organizations